{"filings":[{"id":94212,"accession_number":"0001213900-26-045891","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avalon Quantum AI collaborates with AWS and Caylent for Catch-Up Phase 2 development","event_type":"other_material","confidence":"high","bullets":["Avalon subsidiary Avalon Quantum AI LLC collaborates with AWS to support Phase 2 of Catch-Up agentic AI video platform.","Caylent, Inc., an AWS Premier Tier Partner, appointed to lead the development.","AWS provides $125,000 in funding, contingent on project completion within 7 months; estimated completion in 4 months.","Phase 2 aims to transform Catch-Up from a manually-configured tool into a fully autonomous agentic AI video system.","Management views the collaboration as significant validation of technology and growth strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94208,"accession_number":"0001213900-26-046208","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K/A","filed_at":"2026-04-21T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Avalon GloboCare files pro forma financials for sale of real estate unit to Chairman for $9M","event_type":"other_material","confidence":"high","bullets":["Sale of Avalon RT 9 Properties to Chairman Wenzhao Lu for $9M; excess proceeds ~$2M recorded to additional paid-in capital.","Pro forma eliminates Avalon RT 9's assets ($7.3M) and liabilities ($9.2M); total assets drop to $16.1M.","2025 pro forma net loss from continuing ops unchanged at $17.5M after removing $742K discontinued ops loss.","2024 pro forma net loss improves by $863K to $7.0M, removing real property revenue ($1.33M) and related costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94211,"accession_number":"0001213900-26-045160","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Avalon GloboCare receives Nasdaq notice of non-compliance with minimum bid price rule","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Avalon GloboCare on April 15, 2026 of bid price deficiency per Listing Rule 5550(a)(2).","Closing bid price below $1.00 for 30 consecutive business days (March 1 – April 14, 2026).","Company has 180 calendar days, until October 12, 2026, to regain compliance by closing at $1.00+ for 10 consecutive days.","If not cured by Oct 12, possible second 180-day period if all other listing standards met; potential reverse stock split considered.","Stock continues trading on Nasdaq Capital Market under symbol ALBT with no immediate effect on listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94210,"accession_number":"0001213900-26-039340","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Avalon Globocare sets 2026 Annual Meeting for June 9; shareholder proposal deadline April 12","event_type":"other","confidence":"high","bullets":["2026 Annual Meeting scheduled for June 9, 2026, held virtually; record date is May 15, 2026.","Meeting date shifted more than 30 days from 2025 meeting, so prior proxy deadlines no longer apply.","Deadline for Rule 14a-8 proposals and director nominations is April 12, 2026 (10 days after public announcement).","Proposals must be delivered to company's principal executive office in Freehold, NJ by the deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94209,"accession_number":"0001213900-26-038034","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avalon GloboCare shareholders approve reverse split authorization but no split planned","event_type":"other_material","confidence":"high","bullets":["On March 30, 2026, shareholders approved a future reverse stock split authorization; Board not planning to implement now.","Company states authorization is a standard governance measure to maintain flexibility, not a near-term action.","Avalon reiterates use of social media (Stocktwits, X, Yahoo, Reddit) for material disclosures to investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106419,"accession_number":"0001213900-26-036478","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Avalon Globocare shareholders approve reverse stock split, note conversions, and Lu exchange","event_type":"other_material","confidence":"high","bullets":["All 7 proposals passed at special meeting on March 30, 2026.","Authorized reverse stock split at ratio between 1:2 and 1:25, board to decide.","Approved exchange of 5,000 Series D Preferred held by Chairman Lu for 2,074,689 common shares.","Approved issuance of common shares upon conversion of July 2025 and December 2025 notes.","Approved 450,000 restricted common shares for advisor under consulting agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106406,"accession_number":"0001213900-26-033624","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K/A","filed_at":"2026-03-24T23:59:59+00:00","items":["3.02","1.01","8.01","9.01"],"status":"ready","headline":"Avalon GloboCare corrects share count in $2.8M private placement","event_type":"other_material","confidence":"high","bullets":["The amendment corrects the number of shares reported under Item 3.02 in the original March 2 filing.","Private placement closed Feb 27: issued 490,197 shares, pre-funded warrants for 5,882,353 shares, and Series A-1/A-2 warrants each for 6,372,550 shares at $0.51 exercise.","Net proceeds expected ~$2.8M after fees, for operating expenses and working capital.","H.C. Wainwright as placement agent: 7% cash fee and warrants for 318,628 shares at $0.6375 per share.","On Feb 19,24,26 issued 287,411; 230,739; 750,522 shares upon net exercise of existing warrants with no proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106418,"accession_number":"0001213900-26-025751","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avalon Globocare awards $175K bonus to CFO, increases lead director fees to $95K/yr","event_type":"other_material","confidence":"high","bullets":["CFO Luisa Ingargiola awarded $175,000 bonus for efforts during 2025 fiscal year.","Lead director Steven Saunders annual fees increased to $95,000 per annum.","Compensation changes approved by Board on March 4, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106417,"accession_number":"0001213900-26-022022","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Avalon GloboCare closes $3.25M private placement with up to $6.5M additional warrant proceeds","event_type":"debt","confidence":"high","bullets":["Issued 6,372,550 shares (or pre-funded warrants) at $0.51, plus Series A-1/A-2 warrants for 6,372,550 shares each at $0.51.","Gross proceeds $3.25M; net proceeds ~$2.8M after fees; warrants could add ~$6.5M if fully exercised.","Warrants exercisable only after stockholder approval; Series A-1 expire in 5 years, A-2 in 18 months from approval.","Net proceeds to be used for debt repayment and working capital.","Placement agent H.C. Wainwright; Roth Capital served as financial advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106416,"accession_number":"0001213900-26-020631","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avalon GloboCare subsidiary accepted into AMD AI Developer Program","event_type":"other_material","confidence":"high","bullets":["Avalon Quantum AI LLC accepted into AMD AI Developer Program, gaining access to AMD Developer Cloud credits and compute resources.","Resources include high-performance compute powered by AMD Instinct accelerators and EPYC processors for AI model training.","AQAI plans to use these capabilities for automated commentary video generation, enterprise documentation tools, and workflow automation.","Avalon's interim CEO Meng Li stated the acceptance reinforces AQAI's technical capabilities as the company expands AI-driven media platforms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106415,"accession_number":"0001213900-26-020426","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["1.01","2.03","3.02","5.02","9.01"],"status":"ready","headline":"Avalon Globocare issues $233,910 convertible note; three directors resign, three appointed","event_type":"debt","confidence":"high","bullets":["Note principal $233,910 (incl. $26,910 OID); net proceeds $207,000; matures Feb 15, 2027.","Conversion price at 75% of market price; default interest 22% p.a.; prepayable at discounts.","Directors Stilley, Tauzin, Troy resigned Feb 24; replaced by Felix, Mathews, Sanders on committees.","Resignations not due to any disagreement with company's operations, policies, or management.","Restrictions on asset sales without lender consent; conversion triggers 150% penalty upon default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106414,"accession_number":"0001213900-26-018475","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Avalon GloboCare sells 100% of property subsidiary to Chairman for $9M, relieved of $5.9M mortgage","event_type":"m_and_a","confidence":"high","bullets":["Sold 100% membership interests in Avalon RT 9 Properties, LLC to Chairman Wenzhao Lu for $9M total consideration.","Purchase price consists of $3.1M cash previously advanced plus satisfaction of approx. $5.9M mortgage outstanding.","Company released from all obligations as guarantor on the mortgage; property is principal office location in Freehold, NJ.","Also amended $375K unsecured bridge note to extend first, second, and third payment deadlines by one month each."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106413,"accession_number":"0001213900-26-018003","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Avalon GloboCare issues $233,910 promissory note to Vanquish Funding Group at 13% OID","event_type":"debt","confidence":"high","bullets":["Principal $233,910; purchase price $207,000 (13% original issue discount); 12% one-time interest.","Note matures Feb 15, 2027; seven monthly payments start Aug 15, 2026 ($144,099 then $19,648.50).","Upon default, note converts at 75% of lowest trading price in prior 10 trading days (25% discount).","Also issued 100,000 and 200,000 shares to two consultants for services; no proceeds received.","Net proceeds for working capital; $10,000 fee paid to Digital Offering LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106412,"accession_number":"0001213900-26-017682","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avalon GloboCare subsidiary files provisional patent for audience-adaptive AI video platform","event_type":"other_material","confidence":"high","bullets":["U.S. Provisional Patent Application No. 63/961,892 filed for system that generates multiple personalized commentary video variants while preserving factual integrity.","System analyzes audience engagement data and viewer characteristics to create customized variants that differ in tone, pace, and style from a shared evidence framework.","Potential applications include personalized financial commentary, sports highlight recaps, and brand-safe marketing content.","Subsidiary Avalon Quantum AI LLC filed the patent; interim CEO Meng Li cited meaningful commercial potential.","Filing is a provisional patent; no financial impact or revenue guidance provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106411,"accession_number":"0001213900-26-010568","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avalon GloboCare converts $2.6M of debentures to common stock, slashes debt","event_type":"other_material","confidence":"high","bullets":["Converted $2.6M principal from June 2024 institutional note into shares; $288K repaid in cash.","Eliminates majority of outstanding debentures, strengthening balance sheet and reducing stock overhang.","Company believes substantially all converted shares have been sold by the investor.","Conversion supports recent return to compliance with Nasdaq minimum stockholders' equity requirement.","Interim CEO Meng Li cites improved capital flexibility to execute growth initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106410,"accession_number":"0001213900-26-006488","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Avalon GloboCare terminates merger with YOOV Group; subsidiary files AI patent","event_type":"other_material","confidence":"high","bullets":["Mutually terminated March 2025 merger agreement with YOOV Group Holding Limited, effective Jan 21, 2026.","No termination fee or expense reimbursement paid by either party; mutual release of claims with $500K indemnification cap.","Subsidiary Avalon Quantum AI filed provisional patent (63/961,889) for evidence-constrained AI video commentary.","Patent covers systems with source traceability, audit metadata, and contradiction detection for regulated content markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106409,"accession_number":"0001213900-26-005682","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avalon GloboCare renews FDA registration for KetoAir; plans Q2 2026 launch via Catch-Up AI platform","event_type":"other_material","confidence":"high","bullets":["FDA registration renewed for KetoAir breathalyzer (Reg. No. 3026284320) for ketogenic health management.","Device measures breath acetone (BrAce) to provide real-time, non-invasive metabolic state insights.","Planned B2B and B2C launch in Q2 2026 via Catch-Up, AI-powered short-form video SaaS platform.","Compatible with iOS and Android smartphones; apps available on App Store and Google Play."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106408,"accession_number":"0001213900-26-003178","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Avalon GloboCare regains Nasdaq minimum equity compliance, launches generative AI video platform","event_type":"regulatory","confidence":"high","bullets":["Nasdaq confirmed compliance with minimum stockholders' equity rule 5550(b); previous hearing cancelled.","Company begins marketing for its automated generative AI video platform.","Common stock will continue trading on Nasdaq Capital Market; delisting risk removed.","Interim CEO Meng Li cites strengthened financial position; focus on precision diagnostics and cellular therapy IP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106407,"accession_number":"0001213900-26-001177","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Avalon GloboCare holds annual meeting; all director nominees elected, auditor ratified","event_type":"other","confidence":"high","bullets":["Stockholders elected all six director nominees: Wenzhao Lu, Lourdes Felix, Steven Sanders, William Stilley III, Wilbert Tauzin II, Tevi Troy.","Each director received between 744,869 and 792,744 votes 'for'; broker non-votes totaled 848,349 per nominee.","Ratification of M&K CPAS as independent auditor passed with 1,641,580 'for', 3,555 'against', 10,596 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122765,"accession_number":"0001213900-25-126354","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avalon GloboCare touts RPM's Catch-Up generative AI video platform for KetoAir marketing","event_type":"other_material","confidence":"high","bullets":["Board director Michael Mathews, also RPM CEO, discussed Catch-Up SaaS platform on ProactiveInvestors.","Catch-Up auto-generates recap videos for media companies without manual editing or technical expertise.","Avalon plans to use Catch-Up to amplify marketing for its KetoAir breathalyzer device."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122764,"accession_number":"0001213900-25-121489","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["1.01","5.03","5.02","2.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Avalon GloboCare acquires RPM Interactive for $19.5M in Series E Preferred Stock; resolves Nasdaq equity deficiency","event_type":"m_and_a","confidence":"high","bullets":["Acquired RPM Interactive, a generative AI SaaS platform for automated short-form video, via merger with subsidiary Avalon Quantum AI.","Issued 19,500 shares of Series E Non-Voting Convertible Preferred Stock with $19.5M stated value; convertible at $1.50 per share from May 12, 2026.","Company believes stockholders' equity now exceeds $2.5 million Nasdaq minimum, resolving listing deficiency.","Appointed Michael Mathews (CEO of Aspen Group) to board as director effective immediately after merger.","Also issued $375,000 bridge note (net $300K) to Allen O Cage Jr., with $125K payments due Feb-Apr 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122763,"accession_number":"0001213900-25-116320","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avalon GloboCare reports Q3 2025 KetoAir progress: UK launch and first-responder program","event_type":"other","confidence":"high","bullets":["Launched four-month Holistic Health Reset program for 50 first responders in Nevada using KetoAir for daily metabolic monitoring.","KetoAir breathalyzer became available for purchase in the UK on September 1, 2025 via www.KetoAir.uk, marking first international market entry.","Presented KetoAir at the London Health Optimization Summit on Sept 13-14, 2025.","Mid-program results from Nevada wellness initiative showed individual metabolic health improvements using KetoAir as a tracking tool."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122762,"accession_number":"0001213900-25-113638","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Avalon GloboCare receives Nasdaq delisting notice over equity deficiency","event_type":"regulatory","confidence":"high","bullets":["On Nov 19, 2025, Nasdaq notified Avalon GloboCare (ALBT) it is not in compliance with Listing Rule 5550(b) due to stockholders' equity of ($3,891,270) vs required $2.5M.","The company had until Nov 18 to regain compliance after a May 2025 deficiency notice; failure to do so led to the delisting notification.","Trading of ALBT common stock is subject to suspension/delisting unless the company timely requests a hearing before the Nasdaq Hearings Panel.","The company plans to request a hearing, which will automatically stay any suspension/delisting action pending the hearing and any extension granted.","This disclosure is required under Nasdaq Listing Rule 5810(b)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139452,"accession_number":"0001213900-25-085313","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avalon GloboCare reveals YOOV preliminary FY2025 revenue of $59.3M, net income $3.8M","event_type":"m_and_a","confidence":"high","bullets":["YOOV's preliminary unaudited FY2025 (year ended March 31, 2025): revenue $59.3M, net income $3.8M (206% growth).","Merger with YOOV expected to close in Q4 2025; combined company to focus on AIaaS platform.","YOOV provides AI-powered no-code automation modules for operations, sales, people, and customer service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139442,"accession_number":"0001213900-25-082662","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K/A","filed_at":"2025-08-29T23:59:59+00:00","items":["3.02","1.01","8.01","5.03","9.01"],"status":"ready","headline":"Avalon GloboCare raises $500K via stock sale, amends Series C preferred, and updates note balance","event_type":"other_material","confidence":"high","bullets":["Issued 141,643 shares at $3.53/share to York Sun Investment for $500,000.","Waiver with Mast Hill Fund waives cash penalties on $2.845M note; floor price of $1.00 for conversion adjustments.","As of Aug 29, 2025, note principal balance is $1,421,323.","Potential conversion of note at floor price could yield up to ~2.94M shares (subject to 4.99% beneficial ownership cap).","Amended Series C Convertible Preferred beneficial ownership limitation from 19.99% to 4.99%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139451,"accession_number":"0001213900-25-081433","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avalon GloboCare to launch KetoAir breathalyzer sales in UK starting September 1, 2025","event_type":"other_material","confidence":"high","bullets":["KetoAir breathalyzer sales in UK begin September 1, 2025 at www.KetoAir.uk; device measures breath acetone for ketosis tracking.","Product is manufactured by Qi Diagnostics and uses nano-sensor technology; intended for weight loss, athletic performance, therapeutic use.","Compatible with Apple and Android devices; app available on Apple App Store and Google Play Store.","CEO David Jin: launch builds on US market and meets growing UK demand for ketogenic and low-carb diets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139450,"accession_number":"0001213900-25-075051","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Avalon GloboCare issues 221,000 unregistered shares upon note conversion; total shares 3.69M","event_type":"other_material","confidence":"high","bullets":["Issued 221,000 shares of unregistered common stock between July 30 and August 6, 2025 to a noteholder upon partial conversions of a promissory note.","Total shares outstanding as of August 6, 2025: 3,690,109.","Shares issued under Section 4(a)(2) exemption from registration; no underwriter or public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139449,"accession_number":"0001213900-25-069357","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Avalon GloboCare issues 393,716 unregistered shares in July 2025 for note conversions and services","event_type":"other_material","confidence":"high","bullets":["211,400 shares issued July 16-17 on partial conversion of promissory note; outstanding then 3,286,793.","46,100 shares on July 18 and 47,000 on July 28 from further note conversions.","10,000 commitment shares issued July 24 to noteholders per July 3, 2025 notes.","79,216 restricted shares issued July 24 to consultants for services rendered.","Outstanding common stock grew to 3,469,109 as of July 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139448,"accession_number":"0001213900-25-068450","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Avalon GloboCare extends maturity of senior secured promissory note to August 31, 2025","event_type":"debt","confidence":"high","bullets":["Waiver with Mast Hill Fund extends maturity of promissory note from June 5, 2025 to August 31, 2025.","Original note issued June 5, 2024; extension effective retroactively as of June 5, 2025.","All other terms of the note and securities purchase agreement remain unchanged.","Avoids potential default on $X principal (amount not disclosed)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139447,"accession_number":"0001213900-25-067922","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avalon GloboCare subsidiary signs distribution agreement with Saga Health for KetoAir breathalyzer","event_type":"other_material","confidence":"high","bullets":["Q&A Distribution, LLC entered a wholesale distribution agreement with Saga Health Corporation for the KetoAir breathalyzer.","KetoAir measures breath acetone concentration (BrAce) for ketogenic health management; FDA registration number 3026284320.","Saga Health will use KetoAir in its Holistic Health Reset Program targeting first responders.","Device is compatible with Apple and Android devices and available via App Store and Google Play."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139446,"accession_number":"0001213900-25-066823","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Avalon GloboCare raises $300,000 via Series C Convertible Preferred Stock private placement","event_type":"other_material","confidence":"high","bullets":["Sold 300 shares of Series C Convertible Preferred Stock to Mast Hill Fund for $300,000; net proceeds $290,000 after legal fees.","Conversion to common stock conditioned on shareholder approval; no registration under Securities Act.","Shares subject to transfer restrictions; issuance exempt under Section 4(a)(2) of the Securities Act.","Company disclosed ~2,954,193 common shares outstanding as of July 21, 2025, plus Series C and D preferred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139445,"accession_number":"0001213900-25-065724","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Avalon GloboCare raises $475,500 through sale of 121,200 shares and pre-funded warrants to Brown Stone Capital","event_type":"other","confidence":"high","bullets":["Sold 121,200 shares and pre-funded warrants for 354,300 shares at $475,500; net proceeds $450,500.","Closing occurred July 17, 2025; proceeds after deducting offering expenses.","Registration rights granted; company must file S-1 by earlier of S-4 effectiveness or Sept 26, 2025.","Also issued 515,109 conversion shares on July 15, 2025, bringing total outstanding to 2,954,193 shares (excluding this deal).","Transaction exempt from registration under Section 4(a)(2) as sale to accredited investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139444,"accession_number":"0001213900-25-063521","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avalon GloboCare granted Hong Kong patent for CAR-T/CAR-NK cell technology","event_type":"regulatory","confidence":"high","bullets":["Hong Kong Intellectual Property Department issued standard patent HK40074322 for CAR-T and CAR-NK cell technology.","Patent term of 20 years effective February 21, 2020, providing protection through 2040 in Hong Kong.","Co-developed with strategic partner Arbele Limited; complements existing US and PCT patent protections.","Technology features bispecific Anti-CD19xCD22 CAR design and localized cytokine induction to enhance efficacy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139443,"accession_number":"0001213900-25-062406","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Avalon GloboCare issues $200K convertible notes to two accredited investors","event_type":"debt","confidence":"high","bullets":["Two convertible promissory notes of $100K each issued to Anthony Macaluso and Lawrence Bruno on July 3, 2025.","Notes bear one-time interest charge of $30K each, mature nine months from issue, convertible at $1.00/share.","Issuer granted 5,000 restricted common shares per investor as commitment fee.","Conversion subject to 4.99% beneficial ownership limitation and 19.99% exchange cap unless shareholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157032,"accession_number":"0001213900-25-058049","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Avalon GloboCare and Qi Diagnostics agree to co-develop cannabis breathalyzer for impaired driving detection","event_type":"other_material","confidence":"high","bullets":["Definitive agreement for co-development of VOC nanosensor-based point-of-care cannabis breathalyzer.","Total milestone payments up to $975,000 across four stages: data collection, prototype design, production, human testing.","Qi Diagnostics retains IP; Q&A (Avalon sub) earns up to 50% passive financial interest in IP upon all milestones.","Device aims to support real-time detection of cannabis-impaired driving for law enforcement and workplace safety."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157031,"accession_number":"0001213900-25-051193","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Avalon GloboCare issues 141,643 shares for $500K; amends Series C preferred beneficial ownership limit to 4.99%","event_type":"other_material","confidence":"high","bullets":["Issued 141,643 common shares to York Sun Investment Holding Limited at $3.53/share for $500,000; closing expected by June 6, 2025.","Waived cash penalties under $2.845M Mast Hill Fund note; retained dilutive issuance rights with $1.00 floor price.","Filed certificate of amendment to Series C Preferred Stock reducing beneficial ownership limitation from 19.99% to 4.99% on May 29, 2025.","As of June 4, 2025, Company had ~2,043,971 common shares outstanding; 3,500 Series C and 5,000 Series D preferred shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157030,"accession_number":"0001213900-25-047391","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Avalon GloboCare receives Nasdaq delisting notice for negative stockholders' equity","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of ($3,891,270) as of March 31, 2025, below Nasdaq's $2.5M minimum.","Company must submit a compliance plan by July 7, 2025; Nasdaq may grant extension to Nov 18, 2025.","Failure to regain compliance could lead to delisting, materially impacting liquidity and the pending YOOV merger.","Alternative compliance standards (market value of listed securities $35M or net income $500K) also not met."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157029,"accession_number":"0001213900-25-036394","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avalon GloboCare files S-4 for merger with YOOV; creates AIaaS company","event_type":"m_and_a","confidence":"high","bullets":["Avalon and YOOV filed Form S-4 with SEC for proposed merger, advancing deal first announced March 7, 2025.","Merger will combine Avalon (ALBT) with YOOV's AI automation platform, creating a publicly-traded AIaaS company.","Closing requires Avalon stockholder approval and Nasdaq listing of YOOV post-merger.","YOOV will become a wholly owned direct subsidiary of Avalon, with YOOV surviving as the surviving corporation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157028,"accession_number":"0001213900-25-031754","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avalon GloboCare partners with SpecialtyHealth to deploy KetoAir breathalyzer in police fitness challenge","event_type":"other_material","confidence":"medium","bullets":["KetoAir breathalyzer used in BrAce 4 Impact Challenge for police chiefs, launched April 1, 2024.","Partnership includes SpecialtyHealth, co-founded by Dr. EJ Greenwald, and Pounds Transformation (PT).","KetoAir measures breath acetone to track ketosis; FDA registered (no. 3026284320).","Police chiefs across multiple states participate, using KetoAir as motivational tool for weight management.","Avalon expands Zero to Keto Affiliate Marketing Program with first responder network."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157027,"accession_number":"0001213900-25-030435","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avalon GloboCare granted Chinese patent for CAR-T/NK cell technology; term 20 years","event_type":"other_material","confidence":"high","bullets":["Patent CN 114502188 B issued by CNIPA, effective April 4, 2025, with 20-year protection.","Co-developed with Hong Kong-based Arbele Limited; covers bispecific anti-CD19xCD22 CAR and localized cytokine induction.","Enhances expansion, manufacturing, survival, and efficacy of CAR-T and CAR-NK cells.","Adds to existing U.S. and PCT protections, strengthening global IP portfolio for cell-based immunotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157026,"accession_number":"0001213900-25-026910","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avalon GloboCare launches KetoAir challenge series with Pounds Transformation Clinics","event_type":"other_material","confidence":"high","bullets":["Partnership with Pounds Transformation Clinics for 'BrAce 4 Impact Challenge Series' using KetoAir breathalyzer.","KetoAir now on consignment at all three Pounds Transformation locations in Connecticut.","Official 6-week challenge cycle starts April 1, 2025, following a pilot concluded March 18, 2025.","Dr. Charles Cavo reports patient success with KetoAir, planning new challenges every six weeks.","CEO David Jin highlights positive impact on patient programs and real-time ketone tracking."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175392,"accession_number":"0001213900-25-021943","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["1.01","5.03","7.01","9.01"],"status":"ready","headline":"Avalon GloboCare merges with YOOV; YOOV had $45.7M revenue, $3.4M net income in 2024","event_type":"m_and_a","confidence":"high","bullets":["YOOV CY2024 unaudited revenue $45.7M, net income $3.4M; up from $28.7M rev, ($2.4M) loss in 2023.","Post-merger, YOOV shareholders expected to own ~97.5-97.8% of combined co; Avalon shareholders ~2.2-2.5%.","Phil Wong (YOOV CEO) to become Chairman, CEO, President post-close; board 7 members: 5 from YOOV, 2 from Avalon.","Expected transaction close Q3 2025, subject to stockholder approvals and Nasdaq listing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175391,"accession_number":"0001213900-25-017652","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Avalon GloboCare redeems 40% stake in Laboratory Services MSO for $1.745M","event_type":"other_material","confidence":"high","bullets":["Avalon Lab sells its 40% equity interest in Laboratory Services MSO, LLC back to the entity for $1,745,000 total consideration.","Payment: $95,000 at closing, then $75,000 monthly from March 2025 through December 2026.","Series B Convertible Preferred Stock issued to SCBC Holdings in original purchase is surrendered and canceled for no additional consideration.","The agreement includes mutual releases of claims and five-year non-disparagement obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175390,"accession_number":"0001213900-25-014619","cik":1630212,"company_name":"Avalon GloboCare Corp.","ticker":"ALBT","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avalon GloboCare receives CNIPA patent allowance for CAR-T/NK cell therapy technology","event_type":"other_material","confidence":"high","bullets":["Notice of Allowance from China National Intellectual Property Administration for patent AVAR1901CN, co-developed with Arbele Limited.","Patent covers bispecific anti-CD19xCD22 CAR design and localized cytokine induction to enhance CAR cell cytotoxicity, survival, and proliferation.","Technology aims to improve expansion, manufacturing, and efficacy of CAR-T and CAR-NK cells for cancer treatment.","Extends Avalon's global IP footprint to China, supplementing existing U.S. and PCT protections.","CEO David Jin highlights potential for practical, cost-effective point-of-care cancer solutions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}